The b-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of b-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. . The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral b-globin gene transfer, an adult patient with severe b E /b 0 -thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl
The b-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of b-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound b E /b 0 -thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas 1, 2 . The b Eglobin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated b E -globin with partial instability 1, 2 . When this is compounded with a non-functional b . The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral b-globin gene transfer, an adult patient with severe b E /b 0 -thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl 21 , of which one-third contains vector-encoded b-globin. Most of the therapeutic benefit results from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 in erythroid cells with further increased expression of a truncated HMGA2 mRNA insensitive to degradation by let-7 microRNAs. The clonal dominance that accompanies therapeutic efficacy may be coincidental and stochastic or result from a hitherto benign cell expansion caused by dysregulation of the HMGA2 gene in stem/progenitor cells.
The design of integrative vectors for human b-globin gene transfer has been difficult. The genetic elements required for high and erythroidspecific expression are complex: the b-globin gene with its introns, promoter and b-locus control region (b-LCR) 3, 4 . Lentiviral vectors have proven capable of transferring these elaborate structures with fidelity and high titres 5, 6 . Hence, several mouse models of the bhaemoglobinopathies have been corrected, long-term, by ex vivo transduction of haematopoietic stem cells (HSCs) with b-globin lentiviral vectors [5] [6] [7] [8] [9] [10] . These advances have prompted the prudent initiation of a human clinical trial (Supplementary Note 1).
The general structure of the b-globin-expressing lentiviral vector has been previously described 6, 8 ( Supplementary Fig. 1 ). It is a selfinactivating vector with two copies of the 250-base-pair (bp) core of the cHS4 chromatin insulator 11 implanted in the U3 region. It encodes a mutated adult b-globin (b A(T87Q) ) with anti-sickling properties 6 that can be distinguished from normal adult b-globin (b A ) by highperformance liquid chromatography (HPLC) analysis in individuals receiving red blood cell transfusions and/or b 1 -thalassaemia patients. This report focuses on the first treated patient (P2) who did not receive back-up cells: a male, aged 18 years at the time of treatment, with severe b E /b 0 -thalassaemia. A previous patient (P1) failed to engraft because the HSCs had been compromised by the technical handling of the cells without relation to the gene therapy vector. P1 failed to engraft after 5 weeks and was thus given back-up cells (Supplementary Note 2). P2 was first transfused at age three because of poorly tolerated anaemia (6.7 g dl 21 despite residual fetal haemoglobin (HbF)) and major hepatosplenomegaly. Transfusion requirements rapidly increased to once a month (2-3 red blood cell packs each time; 157 ml of red blood cells per kg the year before transplant). He was splenectomized at age 6. In spite of this, Hb levels decreased several times to as low as 4 g dl 21 , and hydroxurea therapy was ineffective. Iron chelation was initiated at age 8 by parenteral deferoxamine overnight, 5 times a week. The patient did not have a related human-leukocyte-antigen-matched donor and was thus enrolled in this trial after informed consent.
The ex vivo transduction efficiency of bulk bone marrow CD34 1 cells was 0.6 vector per cell after 1 week in culture after gene transfer. The patient was conditioned by intravenous Busulfex (3.2 mg kg 21 day 21 for 4 days) without the addition of cyclophosphamide, before transplantation with autologous gene-modified and cryopreserved cells (3.9 3 10 6 CD34 1 cells per kg). Haematopoietic reconstitution was uneventful ( Supplementary Fig. 2b) .
Patient P2 was transplanted on 7 June 2007. At present, approximately 3 years post-transplantation, the biological and clinical evolution is remarkable, and the patient's quality of life is good. The patient was last transfused on 6 June 2008 (Fig. 1a, c) and has stable Hb levels between 9 and 10 g dl 21 ( Fig. 1a) , of which approximately one-third is comprised of each of the therapeutic Hb-b A(T87Q) (ab (T87Q) Hb dimer), HbE (ab E Hb dimer) and HbF (ac Hb dimer) (Fig. 1b , c and Supplementary Fig. 3a) , with HbA2 (ad Hb dimer) being negligible. No trace of transfused HbA (ab A Hb dimer) has been detected in the blood for the past 17 months (Fig. 1c) . The ratios of c/b E -globin chains remain similar, 33 months post-transplantation, when compared to levels at the time of transplantation, following a transient supplemental rise in c-globin expression shortly after cell engraftment ( Supplementary Fig. 3b ). These observations indicate that the concurrent increase in c-and b , HbE and HbF combined content. Although there is partial correction of the anaemia with concurrent decrease in blood reticulocyte and erythroblast counts ( Supplementary Fig. 2c,  d ), the hypererythroid state remains (Supplementary Note 3). Consistent with previous studies in mice 12 , it is likely that sufficiently corrected b-thalassaemic red blood cells are selected in the blood due to their prolonged lifespan. As expected from the vector design that confers erythroid-specific expression, b
-globin was undetectable in purified blood CD15
1 cells (granulocytes-monocytes) (data not shown). Because the patient had poor tolerance to oral iron chelation (deferasirox), deferiprone was substituted and phlebotomies were performed during the past 6 months to withdraw 200 ml of blood each month (Fig. 1a) . Notably, blood Hb levels have been maintained in spite of a cumulated blood withdrawal of 1.2 l.
Twenty-one months after the last transfusion, the mean corpuscular haemoglobin (MCH) of the last 6 months averaged 28.7 pg, which is within the normal range (27- -globin expression assessed from red blood cells is anywhere between 70.5% and 100% of normal value on a per-gene basis.
The percentage of vector-bearing nucleated blood cells (NBCs) increased progressively after transplant and stabilized at ,11% (Table 1 and Supplementary Fig. 2a ). Among blood subsets, 18.7% and 9.3% of granulocytes-monocytes ( CD15 1 ) and B lymphocytes (CD19 1 ), respectively, contain an integrated vector at 33 months post-transplantation ( Table 1 ). The lower level of gene marking for erythroblasts (CD45
) of blood (,2.9%) versus bone marrow origin (9.8% at 24 months post-transplantation) ( Table 1 ) is in agreement with the contention that genetically corrected erythroblasts appear less frequently in the blood than uncorrected erythroblasts, as the former are capable of differentiating further within the bone marrow compartment into reticulocytes and red blood cells. The low level of T-cell (CD3 1 ) gene marking (,1.7%) ( Table 1) is probably due to the omission of cyclophosphamide from the conditioning regimen. Ten to twenty per cent of bone marrow burst-forming units-erythroid (BFU-Es) and colony-forming units-granulocyte/ monocyte (CFU-GMs) were vector positive by polymerase chain reaction (PCR) ( Table 1) . At 24 months post-transplantation, the proportion of long-term culture-initiating cells (LTC-ICs) (,1/1,000 CD34 1 cells) bearing an integrated vector was 11.1% (Table 1) .
Chromosomal integration sites (IS) of the b A(T87Q) -globin vector in NBCs were analysed by DNA pyrosequencing of ligation-mediated (LM)-PCR products ( Fig. 2a) and subsets thereof. Twenty-four of them were found in both lymphoid and myeloid lineages. Crosscontamination was excluded by real-time quantitative (q)PCR to detect specific provirus/flanking DNA junctions in highly purified NBC subsets. Two of the most abundant and stable multilineage IS (lymphoid and myeloid) lay within the RFX3 and ZZEF1 genes. Their contribution, as monitored by qPCR, remained below 0.5% and 1% for RFX3 and ZZEF1, respectively (not shown).
Importantly, there was dominance over time of an IS at the high mobility group AT-hook 2 (HMGA2) 13 locus in both granulocytesmonocytes and erythroblasts (Fig. 2) . However, the HMGA2 IS was Months post-transplantation . Actual numbers for each Hb species are indicated above the chart. Whole bone marrow (%) 11.5 13.5
LETTERS undetectable by qPCR in fresh or expanded B or T lymphocytes. In myeloid cells, DNA sequence analysis showed that a single vector had integrated in the forward orientation within the ,113-kb third intron of the HMGA2 gene (Fig. 3d) . The integrated vector was intact, except for the presence of only one of the two 250-bp cHS4 insulator cores at each end ( Supplementary Fig. 1 ). The qPCR-mediated analysis of the HMGA2/provirus junction showed that ,45% (plateau) of vectorbearing NBCs were positive for the HMGA2 IS (Fig. 2b) . However, untransduced cells continued to predominate so that only approximately 3%, 8% and 2% of circulating NBCs, granulocytes-monocytes and erythroblasts, respectively, were HMGA2 IS positive 28 months post-transplantation (Fig. 2b, c) . For BFU-Es and CFU-GMs, 8.2% and 8.7%, respectively, are HMGA2 IS positive 24 months post-transplantation (Fig. 2d) ; this accounts for 67% and 78% of vector-bearing CFU-GMs and BFU-Es, respectively. Notably, the frequency of LTCICs positive for HMGA2 IS was 5.6% (Fig. 2d) , thus accounting for ,50% of vector-bearing LTC-ICs (Table 1 ). The mean number of colonies produced by LTC-ICs, or proliferative potential, was not increased when the HMGA2 IS was present (2.6 before transplantation versus 1.5 at 24 months post-transplantation); neither was the mean size of BFU-E colonies (not shown).
Expression of HMGA2 in NBCs was increased by ,10,000-fold, 16 months post-transplantation, as compared to pre-transplant levels (Fig. 3a) . However, HMGA2 was only expressed in erythroblasts, consistent with b-LCR erythroid specificity. HMGA2 mRNA was undetectable in granulocytes-monocytes (not shown) despite a greater frequency of HMGA2 IS in granulocytes-monocytes versus erythroblasts (Fig. 2c) . Consistent with the asymptotic saturation of HMGA2 IS representation in NBCs at the DNA level, RT-qPCR analysis revealed that HMGA2 mRNA expression has also stabilized (Fig. 3b) .
In certain benign tumours, HMGA2 is activated by chromosomal rearrangement within the long third intron, thereby deleting the two distal exons (IV and V) 13 . The missing distal portion of the mRNA contains multiple binding sites for let-7 microRNAs, which trigger physiological HMGA2 RNA degradation 13 . Staggered RT-qPCR reactions specific for each exon junction showed that only exons I to III were present in most of the HMGA2 transcripts in patient P2's NBCs (Fig. 3a) . The predominant HMGA2 mRNA species expressed in the patient's cells was sequenced. It is truncated by alternative splicing of the third intron with a cryptic 39 splice signal (GTAT(C) 6 AG) located within the cHS4 insulator core and cleavage/polyadenylation within the adjacent R region of the left long-terminal-repeat (Fig. 3d) . Western blot analysis with a polyclonal antibody against human HMGA2 revealed a reactive protein in the vicinity of the expected size of 135 amino acids, which comprises the 83 amino acids encoded by the first three HMGA2 exons fused, in-frame, to 52 amino acids corresponding to the residual downstream open reading frame of the FBXL11  TBC1D5  PILRB  MKLN1  IRAK1  ZZEF1  RFX3  NUP98  ATXN10  EPB41L2  EIF1  PHF16  SAE1  GNA12 abnormally spliced transcript (Fig. 3e) . In an effort to estimate the respective contributions of b-LCR-mediated enhancer effect versus post-transcriptional mRNA stabilization by loss of let-7 microRNA target sites, we quantified the ratio of spliced mRNA versus unspliced pre-mRNA HMGA2 by RT-qPCR with differential primers and probes, on the basis of the fact that let-7 miRNAs are only functional in the cytoplasm and are thus only capable of degrading cytoplasmic HMGA2 mRNAs and not the nuclear pre-mRNA 14 . This assay indicated that there was a 36-fold excess of patient P2's truncated HMGA2 mRNA over pre-mRNA compared to the ratio observed in human embryonic stem cells, which express large amounts of full-length HMGA2 mRNA (Fig. 3c) . With ,10,000-fold excess of HMGA2 RNA, the b-LCR thus accounted for a calculated 278-fold enhancer effect in erythroid cells.
We then asked whether dominance of the HMGA2 IS is associated with a breach of haematopoietic homeostasis. As seen above, HMGA2 mRNA expression has asymptotically stabilized for the past 15 months (Fig. 3b) in parallel to the observed stabilization of the presence of the clone (Fig. 2b, c) . Bone marrow cytology and immunotyping were normal, except for bone marrow erythroid hyperplasia as seen in b-thalassaemia (Supplementary Note 3) . Karyotype analysis of bone marrow cells was normal as was high-resolution array-comparative-genomic-hybridization (CGH) analysis of chromosomes. LTC-IC frequency was within the normal range (1 per 1,000 CD34 1 cells), and no decrease in cytokine requirement was observed in clonogenic assays.
We also investigated whether vector integration at the HMGA2 IS was associated with altered globin gene expression with respect to cand b
A(T87Q) -globin levels. As seen above, there was no increase in c/b E -globin ratios in the blood after restoration of steady-state haematopoiesis ( Supplementary Fig. 3b ). In addition, we compared HbF/HbE ratios in single blood-derived BFU-E colonies during the first 6 months post-transplantation-at a time when HMGA2 IS was not yet detectable in erythroid progenitors (n 5 8)-to BFU-Es harvested during a recent 12-28 months post-transplantation period when 50-80% of BFU-Es were modified at the HMGA2 IS (n 5 64). HbF/HbE ratios remained constant between untransduced (n 5 16) and transduced BFU-E colonies, whether the HMGA2 IS was absent or vastly predominant (Supplementary Fig. 3c ).
We finally asked whether b A(T87Q) -globin expression was especially high at the HMGA2 IS compared to other IS. At 4 months post-transplantation, at a time when the HMGA2 IS copy number was too low to be quantified by qPCR (,0.06%), b A(T87Q) -globin expression in circulating red blood cells was at least 13% of the sum of all the endogenous b-like-globins (Fig. 1c) , although patient P2 was still undergoing blood transfusions and accumulation of corrected red blood cells was far from complete. Furthermore, HPLC analysis performed on individual BFU-E colonies showed that the median Hb b
-globin concentration per colony was significantly greater when HMGA2 IS was undetectable (n 5 8) than during the period of HMGA2 IS dominance (n 5 64) ( Supplementary Fig. 3c ), thus indicating that the HMGA2 IS was not especially favourable for high expression of the transferred b A(T87Q) -globin gene. Since the discovery of the b-LCR over 20 years ago 3, 4 , gene therapy for the b-haemoglobinopathies in humans has been long awaited. Here we have shown that a patient with severe b , which compares favourably to the highest levels reported in mouse models with any b-globin lentiviral vector even at high copy number 15 . This amount is expected to provide therapeutic benefit in patients with b The emergence of a partially dominant cell clone requires careful consideration. High, erythroid-specific expression of truncated fusion HMGA2 mRNA and corresponding protein was found to be confined to erythroid cells by a b-LCR-mediated effect-predicted by certain genotoxicity studies 16 but not others 17 -and upon increased stability of the truncated mRNA. Although a single cHS4 insulator 250-bp core has been found to be effective in lentiviral vectors 18 , the loss of one element in the intended cHS4 doublet may have contributed to insulator failure. The presence of the HMGA2 IS in similar proportion among erythroblasts, granulocytes-monocytes and LTC-IC subsets, but not in lymphocytes, leads us to propose that haematopoiesis deriving from the transduced clone initiating cell is myeloidbiased 19, 20 in this patient. The considerable departure from polyclonal distribution exhibited by the HMGA2 IS clone (,50% of all IS in myeloid cells, including LTC-ICs) can either be the consequence of a stochastic event in the context of a low initial number of transduced HSCs 21 , with strictly erythroid-specific HMGA2 expression, or explained by differential expansion/production of myeloid-biased haematopoiesis triggered by dysregulated expression of HMGA2 in upstream progenitors. The truncated HMGA2 mRNA may thus be transiently expressed at abnormally high levels upon b-LCR lineage priming 22 , before the b-LCR enhancing capacity becomes subsequently restricted to the erythroid lineage. Although the lack of sufficient numbers of patient P2's bone marrow cells available for analysis precluded the investigation of vector-derived HMGA2 in the rare common myeloid progenitor, the latter hypothesis may have resulted in myeloid-biased cell expansion (Fig. 4) . Similarly, the respective roles in HMGA2 activation of the b-LCR versus the loss of let-7 miRNA targets are not directly quantifiable in the rare upstream progenitors and stem cells that cannot be isolated to sufficient numbers and degree of purity. Notably, very high compared with undetectable levels of HMGA2 mRNA in erythroblasts versus 22 and/or loss of let-7 microRNA control 13 ). This is because the HMGA2 IS is represented in erythroblasts, granulocyte-monocyte and LTC-IC cells in similar proportions, whereas HMGA2 expression is only detected in erythroid cells. Because the HMGA2 IS is undetectable in lymphocytes, longterm (LT) homeostatic cell expansion is myeloid-biased. The HMGA2 IS initiating cell is likely to be a myeloid-biased LT-HSC 19 /a cell 20 with increased downstream cell production (1, in red) or a common myeloid progenitor with acquired self-renewal capability (2, in red).
granulocyte-monocyte cells, respectively, did not result in a substantial further expansion of erythroid cells.
The clone may remain homeostatic or be a prelude to multistep leukaemogenesis 23, 24 ; clone exhaustion or substitution may also occur. A reassuring fact is that overexpression of a truncated HMGA2 mRNA is correlated with benign tumour phenotypes (for example, lipomas) 13 . In addition, the findings in this gene therapy patient bear certain similarities with paroxysmal nocturnal haemoglobinuria (PNH), a clonal yet benign haematopoietic expansion without increased risk of secondary leukaemia 25 . Paroxysmal nocturnal haemoglobinuria is occasionally associated with multilineage overexpression of a truncated HMGA2 mRNA together with an inactivated PIGA gene 25 . A paroxysmal nocturnal haemoglobinuria patient with almost complete HMGA2 clonal dominance has been observed for 17 years without leukaemic progression (T. Kinoshita, personal communication). This contrasts with overexpression of the full-length HMGA2 mRNA found in several malignancies, presumably because the primary event is the loss of let-7 microRNAs, which control the degradation of multiple oncogeneic mRNAs that include MYC and RAS
26
. The frequent occurrence of homeostatic, clonal haematopoiesis initiated by retroviral activation of proto-oncogenes has been documented in mice 27 , whereas polyclonal haematopoietic reconstitution with clinical efficacy after lentiviral transfer has been recently reported in a human clinical trial 28 . Because perturbations of gene expression triggered by integrated vectors have been detected in human gene therapy trials without apparent ill effects 29 , our understanding of observed cases of polyclonality after integrative gene transfer would benefit from in-depth genome-wide expression studies. Interestingly, we have now identified occurrences of vector integration within the HMGA2 gene, in the absence of leukaemic progression, in several patients of the retroviral gene therapy trial for X-SCID 30 .
As with any other therapeutic approach, patient treatment decisions should ultimately rest on the ethical evaluation of risk/benefit ratios that wouldbeprovidedbyalargerseriesofpatientswithsevereb-thalassaemia.
METHODS SUMMARY
Blood and marrow cells of patient P2 were purified by magnetic cell sorting with specific antibodies. Vector-positive progenitors were scored by PCR. Vector copy numbers and specific insertion sites were quantified by qPCR, RNA expression levels by RT-qPCR, and globin chains and Hb species by HPLC. Integration site analysis was performed by LM-PCR and DNA pyrosequencing. Bone marrow analysis included cytology, immunophenotyping, clonogenic assays, karyotype and high-resolution array-CGH.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
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